Accolade’s (ACCD) Equal Weight Rating Reaffirmed at Stephens

Stephens restated their equal weight rating on shares of Accolade (NASDAQ:ACCD) in a research note released on Wednesday morning,Benzinga reports. Stephens currently has a $7.03 price target on the stock.

Several other research firms have also weighed in on ACCD. Morgan Stanley cut their target price on Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Stifel Nicolaus reissued a “hold” rating and issued a $7.03 price objective (down from $8.00) on shares of Accolade in a research note on Thursday, January 9th. Leerink Partnrs lowered Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a report on Wednesday, January 8th. Finally, Leerink Partners restated a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Twelve investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Accolade currently has an average rating of “Hold” and a consensus price target of $7.46.

Accolade Trading Up 0.4 %

Shares of NASDAQ ACCD opened at $6.90 on Wednesday. The business has a 50 day simple moving average of $5.18 and a 200 day simple moving average of $4.29. Accolade has a 52 week low of $3.08 and a 52 week high of $13.47. The stock has a market cap of $562.97 million, a price-to-earnings ratio of -3.07 and a beta of 2.20. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63.

Accolade (NASDAQ:ACCD) last posted its earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, research analysts predict that Accolade will post -1.2 earnings per share for the current fiscal year.

Insider Activity at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $48,085.20. Following the transaction, the chief executive officer now directly owns 814,316 shares in the company, valued at $2,931,537.60. The trade was a 1.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 41,127 shares of company stock worth $164,674 in the last ninety days. 8.20% of the stock is currently owned by insiders.

Institutional Trading of Accolade

Hedge funds have recently modified their holdings of the company. RPO LLC bought a new position in Accolade in the fourth quarter worth $57,000. ExodusPoint Capital Management LP raised its stake in shares of Accolade by 129.5% in the 4th quarter. ExodusPoint Capital Management LP now owns 169,223 shares of the company’s stock valued at $579,000 after buying an additional 95,498 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Accolade by 54.0% during the 4th quarter. Blair William & Co. IL now owns 81,763 shares of the company’s stock worth $280,000 after acquiring an additional 28,673 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Accolade by 49.9% during the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 17,804 shares of the company’s stock valued at $61,000 after acquiring an additional 5,929 shares in the last quarter. Finally, EntryPoint Capital LLC increased its stake in Accolade by 128.5% in the fourth quarter. EntryPoint Capital LLC now owns 83,787 shares of the company’s stock valued at $287,000 after acquiring an additional 47,113 shares during the period. Institutional investors own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.